{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:52:31Z","timestamp":1779360751735,"version":"3.51.4"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated\/blastic phase evolved from Philadelphia\u2010negative myeloproliferative neoplasms (MPN\u2010AP\/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN\u2010AP\/BP treated frontline with AZA at the standard dosage (75\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ). Median time from diagnosis to AP\/BP evolution was 92.3\u00a0months (IR 29.9\u2010180.1). All patients were evaluable for hematologic response: two patients (5.2%) died early after AZA initiation, 13 patients (33.3%) had a progressive or stable disease, nine (23.1%) had a hematologic improvement (HI), seven (17.9%) achieved a partial response (PR), and eight (20.5%) a complete response (CR). Overall, 24 patients achieved a clinical hematologic response (HI\u00a0+\u00a0PR\u00a0+\u00a0CR), with an overall response rate of 61.5%. Median overall survival (OS) from AZA start of the whole cohort was 13.5\u00a0months (95% CI, 8.2\u201018.7). There was no difference in median OS among patients with HI, PR, or CR (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a0.908). These three subgroups as \u201cresponders\u201d having been considered, a significantly better OS was observed in responder compared with nonresponder patients, with a median OS of 17.6\u00a0months (95% CI, 10.1\u201025.0) versus 4.1\u00a0months (95% CI, 0.4\u201010.0) (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a0.001) Only female gender was significant for both achievement of response (.010) and OS duration (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a0.002). In conclusion, AZA is useful for the management of MPN\u2010AP\/BP, with an overall response rate (HI\u00a0+\u00a0PR\u00a0+\u00a0CR) of 61.5% and a longer OS in responders.\n                  <\/jats:p>","DOI":"10.1002\/hon.2635","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T12:12:49Z","timestamp":1556885569000},"page":"291-295","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of Philadelphia\u2010negative myeloproliferative neoplasms in accelerated\/blastic phase with azacytidine. Clinical results and identification of prognostic factors"],"prefix":"10.1002","volume":"37","author":[{"given":"Alessandro","family":"Andriani","sequence":"first","affiliation":[{"name":"Hematology Fabrizio Spaziani Hospital  Frosinone Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Elli","sequence":"additional","affiliation":[{"name":"Hematology San Gerardo Hospital  Monza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Trap\u00e8","sequence":"additional","affiliation":[{"name":"Hematology Belcolle Hospital  Viterbo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Villiv\u00e0","sequence":"additional","affiliation":[{"name":"UOSD of Hematology ASL Roma 1  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana","family":"Fianchi","sequence":"additional","affiliation":[{"name":"Hematology Sacred Hearth Catholic University of Rome  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-4833","authenticated-orcid":false,"given":"Ambra","family":"Di Veroli","sequence":"additional","affiliation":[{"name":"Hematology University Tor Vergata  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Niscola","sequence":"additional","affiliation":[{"name":"Hematology Sant'Eugenio Hospital  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Centra","sequence":"additional","affiliation":[{"name":"Hematology Polo Universitario Pontino  Latina Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Anaclerico","sequence":"additional","affiliation":[{"name":"Hematology San Giovanni Hospital  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Montanaro","sequence":"additional","affiliation":[{"name":"Department of Hematology Santo Spirito Hospital  Pescara Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenza","family":"Martini","sequence":"additional","affiliation":[{"name":"Hematology Fabrizio Spaziani Hospital  Frosinone Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Aroldi","sequence":"additional","affiliation":[{"name":"Hematology San Gerardo Hospital  Monza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Carmosino","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[{"name":"Hematology Sacred Hearth Catholic University of Rome  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Montanaro","sequence":"additional","affiliation":[{"name":"Hematology Belcolle Hospital  Viterbo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Fo\u00e0","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7741-862X","authenticated-orcid":false,"given":"Roberto","family":"Latagliata","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000204873"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2864"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1441408"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3426"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26354"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-274811"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.03.001"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.12.002"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.08.013"},{"key":"e_1_2_8_13_1","first-page":"1649","article-title":"A phase Ib study to assess the safety and tolerability of Ruxolitinib in combination with Azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN","volume":"130","author":"Drummond MW","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_14_1","article-title":"Efficacy of combined ruxolitinib and decitabine in patients with accelerated and blast\u2010phase myeloproliferative neoplasms: results of a phase II study (MPN\u2010RC 109 trial)","volume":"132","author":"Rampal RK","year":"2018","journal-title":"Blood"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3374-x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.10.002"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2635","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2635","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2635","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T20:08:32Z","timestamp":1694030912000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1002\/hon.2635"],"URL":"https:\/\/doi.org\/10.1002\/hon.2635","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2635\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2635\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2635\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2635\/v2\/response1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]},"assertion":[{"value":"2019-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}